[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-56163-en":3,"doc-seo-56163-105":29,"detail-sidebar-cat-0-en-105":95},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":13,"seo_description":14,"update_tm":27,"read_time":28},56163,687197100911,"Himbo","https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1782698725881665579",7,"Healthcare","Incidence and Risk Factors for Medication-Related Osteonecrosis of the Jaw in Women With Breast Cancer","Prospective cohort research in Region Skne, Sweden, assessed the incidence and risk factors of medication-related osteonecrosis of the jaw (MRONJ) among women with metastatic breast cancer receiving zoledronic acid and/or denosumab. From 2012 to 2015, 242 radiographically confirmed patients were followed until May 31, 2018. MRONJ occurred in 6.6% overall, with higher incidence on denosumab (13.6%) than zoledronic acid (4.1%). Denosumab use increased risk, while corticosteroid use reduced risk; diabetes increased risk.","ARTICLE IN PRESS  \nVol. 00 No. 00 && 2020  \nIncidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study  \nFredrik Hallmer, DDS, PhD,a Olof Bjarnadottir, MD, PhD,b Bengt G€otrick, DDS, PhD,c Per Malmstr€om, MD, PhD,d and Gunilla Andersson, DDS, PhDe  \nObjective. The aim of this study was to prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in patients with metastatic breast cancer treated with zoledronic acid and/or denosumab.  \nStudy Design. In a prospective cohort study performed in Region Skne, Sweden, from January 1, 2012, until December 31, 2015, all patients with breast cancer who had radiographic evidence of bone metastases and were treated with zoledronic acid or denosumab were included and followed up until May 31, 2018 .  \nResults. Of the 242 patients, MRONJ developed in 16 (6.6%) during the 77 months of study. The incidence of MRONJ in patients treated with zoledronic acid was 4.1%, and in patients treated with denosumab, it was 13.6% . The risk of MRONJ was higher inpatients on denosumab than in those treated with zoledronic acid (P = .011) . Corticosteroid use was associated with a decreased risk of MRONJ (P = .008), and diabetes was associated with an increased risk of MRONJ (P = .02) .  \nConclusions. The incidence of MRONJ is 6.6%(>3 times higher) in denosumab-treated patients with breast cancer compared with that in patients treated with zoledronic acid. Corticosteroid use decreased the risk of MRONJ. (Oral Surg Oral Med Oral Pathol Oral Radiol 2020;000:1􀀃6)  \nBreast cancer is the most common cancer among women worldwide and the second most common cause of cancer-related death.1,2 In Sweden, the 5-year survival rate for patients with breast cancer is 90%, but breast cancer survivors remain at risk for late recurrence several years after the primary diagnosis.3 To reduce the risk of local and distant recurrences, endocrine treatment, with or without chemotherapy, is administered. Bone is the most common and often the first location for metastases.4 Antiresorptive medications, that is, intravenous (IV) bisphosphonate and/or subcutaneous denosumab, are frequently used to reduce skeletal-related events (SREs) associated with bone metastases and to treat cancer-related conditions in metastatic settings, such as hypercalcemia.5-7 In a randomized study, patients treated with denosumab had a better quality of life and fewer SREs compared with patients treated with zoledronic acid.8  \naConsultant, Department of Oral and Maxillofacial Surgery, Malm€o University, Faculty of Odontology, Malm€o, Sweden and Department of Oral and Maxillofacial Surgery, Skne University Hospital, Lund, Sweden.  \nbConsultant, Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.  \ncAssociate Professor and Head, Department of Oral Diagnostics, Malm€o University, Faculty of Odontology, Malm€o, Sweden. dProfessor, Department of Haematology, Oncology and Radiation Physics, Skne University Hospital, Lund, Sweden.  \neAssociate Professor, Department of Oral and Maxillofacial Surgery, Malm€o University, Faculty of Odontology, Malm€o, Sweden. Received for publication Nov 17, 2019; returned for revision Feb 13, 2020; accepted for publication Apr 1, 2020 .  \n􀀁 2020 Elsevier Inc. All rights reserved.  \n2212-4403/$-see front matter  \n[https://doi.org/10.1016/j.oooo.2020.04.808](https://doi.org/10.1016/j.oooo.2020.04.808)  \nSeveral studies have shown that in postmenopausal women with early breast cancer, treatment with bisphosphonate decreases recurrence in bone and visceral sites as well as breast cancer mortality.9, 10 Thus, bisphosphonate treatment was recently recommended as adjuvant treatment for postmenopausal patients with breast cancer.11  \nMedication-related osteonecrosis of the jaw (MRONJ), earlier known as bisphosphonate-related osteonecrosis of th","cbCaimuDkVS8UEy9","https://ap.wps.com/l/cbCaimuDkVS8UEy9","pdf",257043,1,6,"English","en",105,"# Objective\n# Study Design\n# Results\n# Conclusions\n# Background and Clinical Relevance","[{\"question\":\"What was the study’s objective regarding MRONJ?\",\"answer\":\"To prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in women with metastatic breast cancer treated with zoledronic acid and/or denosumab.\"},{\"question\":\"How was the study conducted and who was included?\",\"answer\":\"A prospective cohort study in Region Skne, Sweden, included all patients with breast cancer with radiographic bone metastases who received zoledronic acid or denosumab, followed from 2012–2015 until May 31, 2018.\"},{\"question\":\"Which treatment was associated with a higher MRONJ incidence?\",\"answer\":\"Denosumab showed a higher MRONJ incidence (13.6%) compared with zoledronic acid (4.1%), and denosumab increased MRONJ risk (P = .011).\"},{\"question\":\"How did corticosteroid use and diabetes relate to MRONJ risk?\",\"answer\":\"Corticosteroid use was associated with a decreased MRONJ risk (P = .008), whereas diabetes was associated with an increased MRONJ risk (P = .02).\"}]",1783717301,15,{"code":4,"msg":30,"data":31},"ok",{"site_id":24,"language":23,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":90,"head_meta":92,"extra_data":94,"updated_unix":27},"incidence-and-risk-factors-for-medication-related-osteonecrosis-of-the-jaw-in-women-with-breast-cancer","",{"@graph":35,"@context":89},[36,53,68],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,50],{"item":40,"name":41,"@type":42,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":49},"https://docshare.wps.com/document/healthcare/",3,{"item":51,"name":13,"@type":42,"position":52},"https://docshare.wps.com/document/incidence-and-risk-factors-for-medication-related-osteonecrosis-of-the-jaw-in-women-with-breast-cancer/56163/",4,{"url":51,"name":13,"@type":54,"author":55,"headline":13,"publisher":57,"fileFormat":60,"inLanguage":23,"description":14,"dateModified":61,"datePublished":62,"encodingFormat":60,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":56},"Person",{"url":40,"name":58,"@type":59},"DocShare","Organization","application/pdf","2026-07-17","2026-07-10",true,{"@type":65,"interactionType":66,"userInteractionCount":20},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81,85],{"name":72,"@type":73,"acceptedAnswer":74},"What was the study’s objective regarding MRONJ?","Question",{"text":75,"@type":76},"To prospectively determine the incidence of medication-related osteonecrosis of the jaw (MRONJ) and define risk factors in women with metastatic breast cancer treated with zoledronic acid and/or denosumab.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"How was the study conducted and who was included?",{"text":80,"@type":76},"A prospective cohort study in Region Skne, Sweden, included all patients with breast cancer with radiographic bone metastases who received zoledronic acid or denosumab, followed from 2012–2015 until May 31, 2018.",{"name":82,"@type":73,"acceptedAnswer":83},"Which treatment was associated with a higher MRONJ incidence?",{"text":84,"@type":76},"Denosumab showed a higher MRONJ incidence (13.6%) compared with zoledronic acid (4.1%), and denosumab increased MRONJ risk (P = .011).",{"name":86,"@type":73,"acceptedAnswer":87},"How did corticosteroid use and diabetes relate to MRONJ risk?",{"text":88,"@type":76},"Corticosteroid use was associated with a decreased MRONJ risk (P = .008), whereas diabetes was associated with an increased MRONJ risk (P = .02).","https://schema.org",{"og:url":51,"og:type":91,"og:title":13,"og:site_name":58,"og:description":14},"article",{"robots":93,"canonical":51},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":96},[97,101,105,109,114,118,121,126,131,134,138],{"id":20,"doc_module":4,"doc_module_name":45,"category_name":98,"show_sort_weight":99,"slug":100},"Story & Novel",90,"story-novel",{"id":46,"doc_module":4,"doc_module_name":45,"category_name":102,"show_sort_weight":103,"slug":104},"Literature",80,"literature",{"id":52,"doc_module":4,"doc_module_name":45,"category_name":106,"show_sort_weight":107,"slug":108},"Exam",70,"exam",{"id":110,"doc_module":4,"doc_module_name":45,"category_name":111,"show_sort_weight":112,"slug":113},5,"Comic",60,"comic",{"id":21,"doc_module":4,"doc_module_name":45,"category_name":115,"show_sort_weight":116,"slug":117},"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":45,"category_name":12,"show_sort_weight":119,"slug":120},40,"healthcare",{"id":122,"doc_module":4,"doc_module_name":45,"category_name":123,"show_sort_weight":124,"slug":125},8,"Research & Report",30,"research-report",{"id":127,"doc_module":4,"doc_module_name":45,"category_name":128,"show_sort_weight":129,"slug":130},9,"Religion & Spirituality",20,"religion-spirituality",{"id":129,"doc_module":4,"doc_module_name":45,"category_name":132,"show_sort_weight":129,"slug":133},"World Cup","world-cup",{"id":135,"doc_module":4,"doc_module_name":45,"category_name":136,"show_sort_weight":135,"slug":137},10,"Lifestyle","lifestyle",{"id":139,"doc_module":4,"doc_module_name":45,"category_name":140,"show_sort_weight":110,"slug":141},19,"General","general"]